close

Agreements

1 2 3 245
Number of results: 4881

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2020-03-23 Soligenix (USA - NY) the University of Hawai?i at M?noa (USA) COVID-19, coronavirus infection research Infectious diseases Research agreement
2020-02-26 Gemini Therapeutics (USA) - Singapore Eye Research Institute (SG) new targets associated with age-related macular degeneration Age-related Macular Degeneration (AMD), polypoidal choroidal vasculopathy R&D Ophthalmological diseases - Cardiovascular diseases Research agreement
2020-02-12 Sangamo Therapeutics (USA - CA) member of the board nomination Nomination
2019-12-23 Sangamo Therapeutics (USA - CA) Pfizer (USA - NY) gene therapy programs for hemophilia A, including SB-525 hemophilia A licensing - development - commercialisation Rare diseases - Genetic diseases - Hematological diseases Licensing agreement
2019-11-26 Sangamo Therapeutics (USA - CA) member of the board nomination Nomination
2019-11-08 Sangamo Therapeutics (USA - CA) scientific advisory board nomination Nomination
2019-09-30 Sangamo Therapeutics (USA - CA) senior vice president, chief medical officer nomination Nomination
2019-09-13 Gemini Therapeutics (USA) CEO nomination Rare diseases - Genetic diseases- Ophthalmological diseases Nomination
2019-07-31 Sangamo Therapeutics (USA - CA) executive vice president and general counsel nomination Nomination
2019-06-19 Genzyme (USA - MA), a Sanofi company (France) Voyager Therapeutics (USA - MA) gene therapy programs for Parkinson’s disease, Friedreich’s ataxia, Huntington’s disease and other CNS disorders Parkinson’s disease, Friedreich’s ataxia and Huntington’s disease and other CNS disorders development - commercialisation CNS diseases - Neurodegenerative diseases Development agreement
2019-05-20 Voyager Therapeutics (USA-MA) head of R&D nomination Neurological diseases - Neurodegenerative diseases Nomination
2019-04-02 Sangamo Therapeutics (USA - CA) Brammer Bio (USA - CA) large-scale AAV manufacturing manufacturing - production Production agreement
2019-03-12 Sangamo Therapeutics (USA - CA) senior vice president cell therapy nomination Nomination
2019-02-27 Sangamo Therapeutics (USA - CA) Biogen (USA - MA) ST-501, ST-502, and a neuromuscular target tauopathies including Alzheimer’s disease, synucleinopathies including Parkinson’s disease licensing - development - commercialisation Neurological diseases - Neurodegenerative diseases - Neuromuscular diseases Licensing agreement
2019-02-22 Voyager Therapeutics (USA-MA) Abbvie (USA - IL) vectorized antibodies directed at pathological species of alpha-synuclein Parkinson's disease and diseases characterized by the abnormal accumulation of misfolded alpha-synuclein protein development - commercialisation Neurological diseases - Neurodegenerative diseases Development agreement
2019-01-22 Voyager Therapeutics (USA-MA) general counsel nomination Neurological diseases - Neurodegenerative diseases Nomination
2019-01-22 Voyager Therapeutics (USA-MA) Neurocrine Biosciences (USA - CA) VY-AADC, VY-FXN01 Parkinson’s Disease - Friedreich’s Ataxia development, commercialization Rare diseases - Neurological diseases - Neurodegenerative diseases Development agreement
2019-01-15 Voyager Therapeutics (USA-MA) chief medical officer nomination Neurological diseases - Neurodegenerative diseases Nomination
2019-00-22 Sangamo Therapeutics (USA - CA) vice president Research & Development (R&D) nomination Nomination
2018-12-17 Voyager Therapeutics (USA-MA) The Michael J. Fox Foundation for Parkinson’s Research (MJFF) (USA) Parkinson’s Disease Education Consortium, Parkinson’s Progression Markers Initiative Parkinson's disease collaboration Neurological diseases - Neurodegenerative diseases Collaboration agreement